Table 4.

Prevalence ratios for clinic and ambulatory BP monitoring phenotypes among participants with and without reduced eGFR (top panel) and with and without albuminuria (bottom panel)

BP PhenotypesNumber of ParticipantsPrevalence Ratios (95% CIs)
Model 1aModel 2bModel 3cModel 4d
Reduced eGFR (without reduced eGFR, n=472; with reduced eGFR, n=89)
 Uncontrolled clinic BPe105261.05 (0.72 to 1.55)1.10 (0.75 to 1.61)1.08 (0.73 to 1.58)
 Uncontrolled daytime BPe198441.13 (0.88 to 1.45)1.23 (0.96 to 1.57)1.21 (0.94 to 1.55)1.10 (0.87 to 1.40)
 Uncontrolled nighttime BP284611.10 (0.94 to 1.30)1.10 (0.93 to 1.29)1.10 (0.93 to 1.29)1.05 (0.89 to 1.24)
 Nondipping BP pattern318701.12 (0.98 to 1.28)1.09 (0.95 to 1.24)1.10 (0.96 to 1.26)1.09 (0.95 to 1.25)
 White-coat effecte,f3270.99 (0.43 to 2.28)1.05 (0.45 to 2.47)1.04 (0.45 to 2.36)
 Masked uncontrolled hypertensione,f125251.26 (0.90 to 1.78)1.45 (1.04 to 2.02)1.42 (1.00 to 2.00)
 Sustained uncontrolled BPe,f73191.16 (0.75 to 1.78)1.30 (0.84 to 2.01)1.30 (0.85 to 1.99)
Albuminuria (without albuminuria, n=478; with albuminuria, n=83)
 Uncontrolled clinic BPe101301.72 (1.19 to 2.49)1.76 (1.22 to 2.55)1.76 (1.20 to 2.60)
 Uncontrolled daytime BPe196461.33 (1.05 to 1.67)1.36 (1.07 to 1.72)1.30 (1.03 to 1.66)1.09 (0.84 to 1.40)
 Uncontrolled nighttime BP281641.28 (1.09 to 1.50)1.27 (1.08 to 1.50)1.21 (1.02 to 1.44)1.10 (0.93 to 1.31)
 Nondipping BP pattern324641.15 (0.98 to 1.36)1.12 (0.95 to 1.31)1.12 (0.96 to 1.32)1.11 (0.94 to 1.30)
 White-coat effecte,f3271.45 (0.65 to 3.26)1.62 (0.72 to 3.69)1.62 (0.72 to 3.65)
 Masked uncontrolled hypertensione,f127231.26 (0.90 to 1.76)1.34 (0.97 to 1.83)1.26 (0.92 to 1.73)
 Sustained uncontrolled BPe,f69232.01 (1.40 to 2.89)2.06 (1.42 to 2.99)2.02 (1.36 to 2.99)
  • Reduced eGFR was defined as levels <60 ml/min per 1.73 m2. Albuminuria was defined as an albumin-to-creatinine ratio ≥30 mg/g.

  • a Model 1 included adjustment for age and sex.

  • b Model 2 included adjustment age, sex, education, smoking status, physical activity, alcohol consumption, and body mass index.

  • c Model 3 included adjustment for the variables in model 2 and history of stroke, history of myocardial infarction, diabetes, and total and HDL cholesterol.

  • d Model 4 included adjustment for the variables in Model 3 and clinic systolic and diastolic BP.

  • e Model 4 not performed because clinic systolic and diastolic BP were used to define these phenotypes.

  • f The prevalence ratios for white-coat effect, masked uncontrolled hypertension and sustained uncontrolled BP are compared with sustained controlled BP.